P Reimer1, M K Virarkar2, M Binnenhei3, M Justinger4, M R Schön4, K Tatsch5. 1. Institute for Diagnostic and Interventional Radiology, Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Moltkestraße 90, 76133, Karlsruhe, Germany. Peter.Reimer@partner.kit.edu. 2. Department of Diagnostic Radiology, M D Anderson Cancer Center, Houston, TX, USA. 3. Medical Clinic III, Department of Hematology, Oncology, Infectious Disease and Palliative Medicine, Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Karlsruhe, Germany. 4. Department of General and Visceral Surgery, Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Karlsruhe, Germany. 5. Department of Nuclear Medicine, Klinikum Karlsruhe, Academic Teaching Hospital of the University of Freiburg, Karlsruhe, Germany.
Abstract
INTRODUCTION: To investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE) therapy. MATERIALS AND METHODS: Between 2005 and 2016, 21 patients with ICC were treated with Y-90 RE only and their survival data were analyzed. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RESULT: The overall median survival was 15 months. Survival was significantly (p = 0.009) prolonged in patients with tumor burden of ≤ 25% (n = 8, OS 37.5 months) versus those with a tumor burden of 25-50% (n = 13, OS 15 months). The other variables: tumor morphology (infiltrative vs. peripheral), tumor distribution (solitary vs. multifocal), lobes involved (unilobar vs. bilobar), FDG PET status (FDG avid vs. non-avid), RE treatment sessions (1 session vs. 2 sessions), metastases (metastasis vs. no metastasis) and RECIST criteria, had no significant impact on survival. CONCLUSION: Tumor burden represents a key prognostic factor of survival in therapy-naïve patients with unresectable ICC treated with Y-90 RE therapy only.
INTRODUCTION: To investigate prognostic factors in unresectable intrahepatic cholangiocarcinoma (ICC) therapy-naïve patients after yttrium-90 (Y-90) radioembolization (RE) therapy. MATERIALS AND METHODS: Between 2005 and 2016, 21 patients with ICC were treated with Y-90 RE only and their survival data were analyzed. Patients were stratified and response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RESULT: The overall median survival was 15 months. Survival was significantly (p = 0.009) prolonged in patients with tumor burden of ≤ 25% (n = 8, OS 37.5 months) versus those with a tumor burden of 25-50% (n = 13, OS 15 months). The other variables: tumor morphology (infiltrative vs. peripheral), tumor distribution (solitary vs. multifocal), lobes involved (unilobar vs. bilobar), FDG PET status (FDG avid vs. non-avid), RE treatment sessions (1 session vs. 2 sessions), metastases (metastasis vs. no metastasis) and RECIST criteria, had no significant impact on survival. CONCLUSION:Tumor burden represents a key prognostic factor of survival in therapy-naïve patients with unresectable ICC treated with Y-90 RE therapy only.
Authors: Héloïse Bourien; Xavier Palard; Yan Rolland; Fanny Le Du; Luc Beuzit; Thomas Uguen; Samuel Le Sourd; Marc Pracht; Vincent Manceau; Astrid Lièvre; Karim Boudjema; Etienne Garin; Julien Edeline Journal: Eur J Nucl Med Mol Imaging Date: 2018-10-29 Impact factor: 9.236
Authors: Matthias P Fabritius; Najib Ben Khaled; Wolfgang G Kunz; Jens Ricke; Max Seidensticker Journal: J Clin Med Date: 2021-11-26 Impact factor: 4.241
Authors: Camille Goislard de Monsabert; Yann Touchefeu; Boris Guiu; Boris Campillo-Gimenez; Olivier Farges; David Tougeron; Isabelle Baumgaertner; Ahmet Ayav; Luc Beuzit; Marc Pracht; Astrid Lièvre; Samuel Le Sourd; Karim Boudjema; Yan Rolland; Etienne Garin; Eveline Boucher; Julien Edeline Journal: Curr Oncol Date: 2021-11-08 Impact factor: 3.677
Authors: Michael Köhler; Fabian Harders; Fabian Lohöfer; Philipp M Paprottka; Benedikt M Schaarschmidt; Jens Theysohn; Ken Herrmann; Walter Heindel; Hartmut H Schmidt; Andreas Pascher; Lars Stegger; Kambiz Rahbar; Moritz Wildgruber Journal: J Clin Med Date: 2019-12-25 Impact factor: 4.241